These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11217140)

  • 1. Hepatic lipase as a focal point for the development and treatment of coronary artery disease.
    Zambon A; Brown BG; Deeb SS; Brunzell JD
    J Investig Med; 2001 Jan; 49(1):112-8. PubMed ID: 11217140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
    Zambon A; Deeb SS; Brown BG; Hokanson JE; Brunzell JD
    Circulation; 2001 Feb; 103(6):792-8. PubMed ID: 11171785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.
    Kimura H; Miyazaki R; Imura T; Masunaga S; Shimada A; Mikami D; Kasuno K; Takahashi N; Hirano T; Yoshida H
    Nephrology (Carlton); 2011 Aug; 16(6):558-66. PubMed ID: 21352420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.
    Zambon A; Deeb SS; Hokanson JE; Brown BG; Brunzell JD
    Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1723-9. PubMed ID: 9812910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease.
    Zambon A; Austin MA; Brown BG; Hokanson JE; Brunzell JD
    Arterioscler Thromb; 1993 Feb; 13(2):147-53. PubMed ID: 8427851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.
    Brunzell JD; Zambon A; Deeb SS
    Biochim Biophys Acta; 2012 Mar; 1821(3):365-72. PubMed ID: 21986251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.
    Zambon A; Deeb SS; Pauletto P; Crepaldi G; Brunzell JD
    Curr Opin Lipidol; 2003 Apr; 14(2):179-89. PubMed ID: 12642787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia.
    Allayee H; Dominguez KM; Aouizerat BE; Krauss RM; Rotter JI; Lu J; Cantor RM; de Bruin TW; Lusis AJ
    J Lipid Res; 2000 Feb; 41(2):245-52. PubMed ID: 10681408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hormone replacement therapy and hepatic lipase polymorphism on serum lipid profiles in postmenopausal Japanese women.
    Somekawa Y; Umeki H; Kobayashi K; Tomura S; Aso T; Hamaguchi H
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4766-70. PubMed ID: 12364471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of preheparin serum lipoprotein lipase mass in normocholesterolemic patients with coronary artery disease].
    Hitsumoto T; Yoshinaga K; Sakurai T; Aoyagi K; Matsumoto J; Iizuka T; Kaku M; Sugiyama Y; Kanai M; Uchi T; Noike H; Ohsawa H; Watanabe H; Shirai K
    J Cardiol; 2002 Jul; 40(1):1-9. PubMed ID: 12166243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients.
    Jansen H; Verhoeven AJ; Weeks L; Kastelein JJ; Halley DJ; van den Ouweland A; Jukema JW; Seidell JC; Birkenhäger JC
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2837-42. PubMed ID: 9409263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between -514C-->T polymorphism of the hepatic lipase gene and coronary artery disease in a Turkish population.
    Gündoğdu F; Gurlertop Y; Pirim I; Aksakal E; Dogan H; Islamoglu Y; Ozkan A; Senocak H
    Acta Cardiol; 2008 Apr; 63(2):197-202. PubMed ID: 18468200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between a novel polymorphism of hepatic lipase gene and coronary artery disease.
    Su ZG; Zhang SZ; Hou YP; Zhang L; Huang DJ; Liao LC; Xiao CY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Nov; 34(6):780-5. PubMed ID: 12417924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.